Global strategy and plan of action on public health, innovation and intellectual property

On behalf of Global Health Council, supported by its member the Infectious Diseases Society of America, we appreciate the recommendations of the expert review panel on the global strategy and plan of action on public health, innovation and intellectual property. Representing more than 11,000 infectious disease physicians and scientists, IDSA recognizes the urgent need to develop the policies and tools required for addressing the most pressing global infectious disease crises, from developing a vaccine to prevent tuberculosis, to promoting incentives for the development of new antibiotics to address resistance. IDSA supports the panel’s recommendation to prioritize research and development needs of Type III diseases that are overwhelmingly infectious diseases.

IDSA also supports the panel recommendation to support collaborations between internationally recognized centers for R&D and institutions in developing countries. Multisectoral, global partnerships are not only central for developing and scaling up use of health innovations, they are essential for strengthening health capacity in developing countries.

IDSA strongly supports the recommendation to implement delinking mechanisms for the sales of certain products from developer return on investment, particularly for new antibiotics that address antimicrobial resistance. Such an approach can incentivize urgently needed R&D while also promoting antibiotic stewardship and patient access to needed medicines globally. IDSA is advancing a U.S. legislative proposal to establish a delinkage mechanism for antibiotics.

We support the call to Member States for dedicated R&D funding relevant to the health needs of developing countries. We will continue to advocate to the U.S. government for adequate resources for global health R&D.